An observational study in Critical Illness, COVID-19 and Central Nervous System Injury, sponsored by University of Rostock. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-01-29.
Sponsored by University of Rostock · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.
Among the 226 studies in COVID-19 with a site in Germany, this one is the 70th largest by enrollment of the 94 observational ones that give a count, is one of 109 that started in 2020, is one of 94 observational ones, and was the 33rd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Germany, United States, Argentina and 21 more countries
Ages 18+
Technical University of Munich · Sites in Germany, Austria, Belgium and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
226 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 48 · Phase 3 46 · Phase 4 5
First in 2016; this study’s year is marked. 109 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is below the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 135 across the 130 interventional studies, 410 across the 94 observational. Of the 153 that completed or were terminated, 48 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 226 have an industry lead sponsor. The 10 most frequent:
University of Rostock is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
University of Rostock has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
9 of the studies in COVID-19 with a site in Germany that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05389319University Hospital TuebingenA Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 226 studies in COVID-19 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging.
Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.
This is a multicenter observational study evaluating the incidence and severity of neurocognitive impairment in adult and pediatric patients with COVID-19. All study participants will be assessed by clinical and neurological examination as well as comprehensive laboratory tests using biomarkers of neuroaxonal injury at study day 1 (day of study inclusion), day 3, day 7 and day of hospital discharge. A panel of biomarkers (among others NSE, S100B and neurofilament proteins) will be measured. Clinical assessment will be performed using validated delirium tests (among others CAM-ICU, ICDSC) and scales to assess the neurocognitive performance of study participants before and three months after study inclusion (among others Short Blessed Test).
A group of patients with a comparable severity of disease but without the detection of SARS-Cov-2 will serve as control group and will undergo the same clinical and laboratory examinations.
We hypothesize, that:
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
This study's enrollment of 118 is below the median of 268 across 3,209 observational studies indexed under COVID-19.
Browse COVID-19 studies →University of Rostock is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All patients with suspected SARS-CoV-2 infection who are admitted to the study centers will be screened for study eligibility according to the inclusion and exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* adult patients of every age * admission to hospital with suspected COVID-19 disease * confirmed SARS-CoV-2 infection within 48 hours after admission
* adult patients of every age * admission to hospital with suspected COVID-19 disease * exclusion of SARS-CoV-2 infection within 48 hours after admission
* pediatric patients * admission to hospital with suspected COVID-19 disease * confirmed SARS-CoV-2 infection within 48 hours after admission
* pediatric patient * admission to hospital with suspected COVID-19 disease * exclusion of SARS-CoV-2 infection within 48 hours after admission
Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19
Assessment of neurocognitive impairment using validated tools
Time frame: Day 90
Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19
Measurement of biomarker levels (e.g. NSE, S100B, neurofilament proteins) derived from blood samples
Time frame: Change from baseline biomarker levels at day 28
Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19
Assessment of the neurocognitive performance of patients using validated tests (e.g. Short Blessed Test)
Time frame: Day 90
Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19
Assessment of the change in the neurocognitive performance of patients using validated tests (e.g. IQCODE)
Time frame: Change from baseline IQCODE results at day 90
Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge
Assessment of the overall quality of life using validated tests \[e.g. Modified Rankin Scale with a range from 0 (no symptoms) to 6 (dead)\]
Time frame: Day 90
Length of hospital stay in patients with COVID-19 compared to patients without COVID-19
Cumulative days in hospital
Time frame: 1 year
90-day survival in patients with COVID-19 compared to patients without COVID-19
Survival after 90 days
Time frame: Day 90
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2020 to primary completion in Mar 2021, 11 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 11 months is below that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Rostock